One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Future perspectives on care for patients with psoriasis. What did we learn during the COVID-19
Peter C. M. van de Kerkhof
doi : 10.1080/09546634.2021.1945655
Volume 32, 2021 - Issue 5-Page 477
Psoriasis patient preferences for topical drugs: a systematic review
Mathias Tiedemann Svendsen,Steven R. Feldman,Sylvia Naiga TiedemannORCID Icon,Anne Sofie Stochholm S?rensen,Cecilie Marie Ringgaard Rivas &Klaus Ejner AndersenORCID Icon
doi : 10.1080/09546634.2019.1675855
Volume 32, 2021 - Issue 5-Pages 478-483
Topical drugs are recommended first-line treatment for mild-to-moderate psoriasis. However, patient preferences for the topical drugs differ, since a wide variety of topical drugs and topical drug formulations are available.
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
Luis PuigORCID Icon,Jashin J. Wu,Melinda J. Gooderham,Yin You,Yaung-Kaung Shen,Bruce Randazzo &Francisco Kerdel
doi : 10.1080/09546634.2019.1679336
Volume 32, 2021 - Issue 5-Pages 484-491
In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis.
Review of treatments for generalized pustular psoriasis
Donovan G. Kearns,Vipawee S. Chat,Peter D. Zang,George Han &Jashin J. Wu
doi : 10.1080/09546634.2019.1682502
Volume 32, 2021 - Issue 5-Pages 492-494
Generalized pustular psoriasis (GPP) is an uncommon variant of psoriasis that is characterized clinically by sterile pustule formation superimposed over inflamed, erythematous skin.
Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy
Vipawee S. ChatORCID Icon,Donovan G. Kearns,Shelley K. Uppal &Jashin J. Wu
doi : 10.1080/09546634.2019.1687812
Volume 32, 2021 - Issue 5-Pages 495-496
Dermatology nurses view on factors related to Danish psoriasis patients’ adherence to topical drugs: a focus group study
Mathias Tiedemann Svendsen,Steven R. Feldman,Sylvia Naiga Tiedemann,Anne Sofie Stochholm S?rensen,Cecilie Marie Ringgaard Rivas &Klaus Ejner Andersen
doi : 10.1080/09546634.2019.1687817
Volume 32, 2021 - Issue 5-Pages 497-502
Topical medications are first-line treatment for mild-to-moderate psoriasis, but adherence is low, which negatively affects patients’ outcomes and quality of life. Nurses can play a central role in patient care, particularly in improving adherence.
A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis
Catherine M. LudwigJeffrey M. Krase,Kyla N. Price,Peter A. Lio &Vivian Y. Shi
doi : 10.1080/09546634.2019.1682498
Volume 32, 2021 - Issue 5-Pages 503-506
no abstract
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
M. C. Fargnoli,M. Esposito,S. Ferrucci,G. Girolomoni,A. Offidani,A. Patrizi,K. Peris,A. Costanzo,G. Malara,G. Pellacani,M. Romanelli,P. Amerio,A. Cristaudo,M. L. Flori,A. Motolese,P. Betto,C. Patruno,P. Pigatto,R. Sirna,G. Stinco,I. Zalaudek,L. Bianchi,V. Boccaletti,S. P. Cannav?,F. Cusano,S. Lembo,R. Mozzillo,R. Gallo,C. Potenza,F. Rongioletti,R. Tiberio,T. Grieco,G. Micali,S. Persechino,M. Pettinato,S. Pucci,E. Savi,L. Stingeni,A. Romano,G. Argenziano &On behalf of the Dupilumab Italian National Access Program (Dup-INAP group)
doi : 10.1080/09546634.2019.1682503
Volume 32, 2021 - Issue 5-Pages 507-513
Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Pharmacy costs of systemic and topical medications for atopic dermatitis
Elizabeth Mata,Tiffany Y. Loh,Catherine Ludwig,Kyla N. Price,Jennifer M. Fernandez,Jeffery M. Krase &Vivian Y. Shi
doi : 10.1080/09546634.2019.1687811
Volume 32, 2021 - Issue 5-Pages 514-516
The ambulatory care burden of nail conditions in the United States
Shari R. Lipner,Julie E. HancocORCID Icon &Alan B. Fleischer
doi : 10.1080/09546634.2019.1679337
Volume 32, 2021 - Issue 5-Pages 517-520
Millions of Americans seek medical care for their nail conditions each year, consulting physicians of many different specialties.
Monofilament threads in treatment of female hair loss
Mohamed Metwalli,Fathia M. KhattabORCID Icon &Samira Mandour
doi : 10.1080/09546634.2019.1682499
Volume 32, 2021 - Issue 5-Pages 521-525
Recently, thread treatment has been commonly used in Korean medicine for cosmetic reasons such as decreasing skin wrinkles. It was noted that an inserted thread caused constant stimulation, followed by assistance for connective tissue regeneration. However, its role in hair development has not yet been revealed.
Meta-analysis of 308-nm excimer laser therapy for alopecia areata
A. K. Gupta &J. L. Carviel
doi : 10.1080/09546634.2019.1687819
Volume 32, 2021 - Issue 5-Pages 526-529
Background: Alopecia areata (AA) is an autoimmune disease that can result in spontaneous hair loss. Currently, there is no US Food and Drug Administration (FDA) approved treatment, however new treatments are being investigated. Excimer laser and excimer lamp treatment have been suggested and have the benefit of mild/few adverse effects.
Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)
Sophia Wilden,Marina Friis,Andrea Tuettenberg,Petra Staubach-RenzO,Joanna Wegner,Stephan Grabbe &Esther von Stebut
doi : 10.1080/09546634.2019.1677842
Volume 32, 2021 - Issue 5-Pages 530-537
Hidradenitis suppurativa is a chronic inflammatory disease with high burden. Treatment options are often unsatisfactory. We assessed the effect of a combination therapy of intense pulsed light (IPL) and radiofrequency (RF).
Adverse reactions associated with the esthetic use of soft tissue fillers and neurotoxins: a 53-year retrospective analysis of MedEffect™, Health Canada’s reporting database
Kaitlyn M. Enright,John Sampalis &Andreas Nikolis
doi : 10.1080/09546634.2019.1682501
Volume 32, 2021 - Issue 5-Pages 538-543
This is the first study to evaluate Health Canada’s national reporting database, MedEffect™, to assess the safety and efficacy of esthetic injectables.
A retrospective study of FQSRL and IPL in the treatment of Café-au-lait macule
Tianshu Gu,Jinping Yuan,Yanping Zhang,Yuan-Hong Li,Yan Wu,Xing-Hua Gao &Hong-Duo Chen
doi : 10.1080/09546634.2019.1687813
Volume 32, 2021 - Issue 5- Pages 544-547
The application of fractional Q-switched ruby laser (FQSRL) or intense pulsed light (IPL) on Café-au-lait macule (CALM) is rational and the data are lacking.
The efficacy and safety of DermalaxTM DEEP in the correction of moderate to severe nasolabial folds: a multicenter, randomized, double-blind clinical study
Ju Qiao,Feng Li,Hong-Zhong Jin,Xiu-Min Yang,Hong Fang,Li Li,Wei Zhang,Xin-Feng Wu,Min Zheng &Qian-Nan Jia
doi : 10.1080/09546634.2019.1687814
Volume 32, 2021 - Issue 5-Pages 548-555
To investigate the efficacy and safety of Dermalax in the correction of moderate to severe nasolabial folds (NLFs) compared to Restylane.
Liposuction for large facial involuted infantile hemangiomas in children: clinical evaluation and management strategies
Wei Gao,Yajing Qiu,Yunbo Jin &Xiaoxi Lin
doi : 10.1080/09546634.2019.1687816
Volume 32, 2021 - Issue 5-Pages 556-560
Large involuted infantile hemangioma (IH) can cause facial disfigurement and functional impairment and constitute a major concern to children and parents. Liposuction for large involuted IH has been reported in some case reports. However, systematic study is seldom and the patient outcome is uneven.
Efficacy and safety of neuronox® for lateral canthal lines: a phase I/III, multicenter, randomized, double-blind, active-controlled study
Youngkyoung Lim,Jong Hee Lee,Woo Shun Lee,Weon Ju Lee,Hei Sung Kim,Min Kyung Shin,Sik Haw&Chang-Hun Hu
doi : 10.1080/09546634.2019.1687818
Volume 32, 2021 - Issue 5-Pages 561-567
Neuronox® has not yet been investigated for its efficacy and safety in the treatment of lateral canthal lines (LCL).
Usefulness of video thermography in the evaluation of platelet-rich plasma effectiveness in vulvar lichen sclerosus: preliminary study
M. Tedesco,V. Garelli,F. Elia,G. Chicherchia,M. L. Foddai,A. Latini,A. Morrone &E. Migliano
doi : 10.1080/09546634.2019.1685644
Volume 32, 2021 - Issue 5-Pages 568-571
Lichen sclerosus (LS) is a chronic-relapsing and potentially serious skin disease that has a preference for genital skin. Currently, there is no standardized method for assessing the effects of therapies.
Contemporary management of actinic keratosis
Cristian Navarrete-Dechent,Ashfaq A. Marghoob &Michael A. Marchetti
doi : 10.1080/09546634.2019.1682504
Volume 32, 2021 - Issue 5-Pages 572-574
Actinic keratosis (AK) is a skin lesion characterized by itraepithelial keratinocyte dysplasia and molecular alterations shared with normal chronically sun-damaged skin and squamous cell carcinoma (SCC). AK can undergo spontaneous regression, stable existence, or malignant transformation to cutaneous SCC with progression rates to SCC ranging from 0% to 0.5% per lesion-year and AK spontaneous regression of 15–63%. As AK is a potential precursor of invasive SCC, it is commonly treated to mitigate the risk of malignant progression, including metastasis and death. There is a myriad of available spots (e.g. cryotherapy) and field (e.g. 5-fluorouracil, imiquimod photodynamic therapy) treatments for AK. Recently published randomized clinical trials have helped bridge the gap on AK management. In this viewpoint, we sought to summarize the most up-to-date evidence in the management of AK.
